Literature DB >> 22090727

Transcoronary ethanol ablation for ventricular tachycardia.

Johnson Francis1, Frederic Sacher.   

Abstract

Entities:  

Keywords:  transcoronary ethanol ablation; ventricular tachycardia

Year:  2011        PMID: 22090727      PMCID: PMC3214611     

Source DB:  PubMed          Journal:  Indian Pacing Electrophysiol J        ISSN: 0972-6292


× No keyword cloud information.
Radiofrequency catheter ablation is a well established modality of treatment for ventricular tachycardia (VT). But it may not be successful in certain cases when the re-entrant circuit is situated deep within the myocardium and inaccessible to both endocardial and epicardial ablation. One of the earliest reports on transcoronary ethanol ablation of refractory ventricular tachycardia was by Inoue H et al in 1987 [1] in experimental animals followed by Brugada P et al in humans in1989 [2]. Brugada P et al identified the artery supplying the arrhythmogenic area and injected 1.5-6ml of sterile 96% ethanol, which cured the arrhythmia in two of the three patients. In the third one, arrhythmia recurred when a new collateral blood supply developed to the arrhythmogenic region, which was successfully treated by a repeat procedure. They had done a careful transcoronary mapping with saline prior to ablation in all cases. One of their patients developed temporary complete atrioventricular block after high septal ethanol ablation, requiring pacemaker. Qi XQ et al [3] also reported successful transcoronary ethanol ablation in a patient with refractory ventricular tachycardia, who had no recurrence at two year follow up. They had demonstrated similar results in experimental animals earlier [4]. de Paola AA et al [5] documented ethanol ablation of ventricular tachycardia in chronic chagasic myocarditis. Programmed ventricular stimulation done after two weeks failed to induce ventricular tachycardia in their case. Nellens P et al [6] identified the culprit vessel by a combination of coronary angiography, left ventriculography, programmed electrical stimulation with endocardial mapping and pace mapping. Ethanol ablation was successful in all the ten of the twelve cases in which the artery could be identified. Six of them remained free of tachycardia and seven of them were alive, at a follow up period ranging from 2 to 44 months. Verna E et al [7] described a case of fatal myocardial rupture and cardiac tamponade following successful alcohol ablation of refractory ventricular tachycardia and advised caution while proceeding with alcohol ablation. Recent reports by Sacher F et al [8] and Tokuda M et al [9] have once again highlighted the role of transcoronary ethanol ablation of refractory ventricular tachycardia after failed radiofrequency catheter ablation. Most of these were in the setting of ischemic cardiomyopathy with scar related re-entry. Reports of successful transcoronary ethanol ablation in ventricular tachycardias in hypertrophic cardiomyopathy [10] and ventricular tachycardia arising from the aortomitral continuity [11] are also available. Overall data would suggest that transcoronary ethanol ablation may be considered in refractory ventricular tachycardias which are not amenable to conventional radiofrequency catheter ablation due to deep seated foci of origin.
  11 in total

1.  Myocardial dissection following successful chemical ablation of ventricular tachycardia.

Authors:  E Verna; S Repetto; C Saveri; N Forgione; S Merchant; G Binaghi
Journal:  Eur Heart J       Date:  1992-06       Impact factor: 29.983

2.  Transcoronary chemical ablation of ventricular tachycardia in chronic chagasic myocarditis.

Authors:  A A de Paola; J A Gomes; M H Miyamoto; E E Fo
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

3.  Transcoronary chemical ablation of ventricular tachycardia.

Authors:  P Brugada; H de Swart; J L Smeets; H J Wellens
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

4.  Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation: an update.

Authors:  Michifumi Tokuda; Piotr Sobieszczyk; Andrew C Eisenhauer; Pipin Kojodjojo; Keiichi Inada; Bruce A Koplan; Gregory F Michaud; Roy M John; Laurence M Epstein; Frédéric Sacher; William G Stevenson; Usha B Tedrow
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-10-07

5.  Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy.

Authors:  Keiichi Inada; Jens Seiler; Kurt C Roberts-Thomson; Daniel Steven; Jonathan Rosman; Roy M John; Piotr Sobieszczyk; William G Stevenson; Usha B Tedrow
Journal:  J Cardiovasc Electrophysiol       Date:  2010-08-30

6.  Ventricular tachycardia arising from the aortomitral continuity in structural heart disease: characteristics and therapeutic considerations for an anatomically challenging area of origin.

Authors:  Daniel Steven; Kurt C Roberts-Thomson; Jens Seiler; Keiichi Inada; Usha B Tedrow; Richard N Mitchell; Piotr S Sobieszczyk; Andrew C Eisenhauer; Gregory S Couper; William G Stevenson
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12

7.  Transcoronary chemical ablation of arrhythmias.

Authors:  P Nellens; S Gürsoy; E Andries; P Brugada
Journal:  Pacing Clin Electrophysiol       Date:  1992-09       Impact factor: 1.976

8.  Intracoronary ethyl alcohol or phenol injection ablates aconitine-induced ventricular tachycardia in dogs.

Authors:  H Inoue; B F Waller; D P Zipes
Journal:  J Am Coll Cardiol       Date:  1987-12       Impact factor: 24.094

9.  Transcoronary ethanol ablation of experimental ventricular tachycardia after epicardial ice mapping and localizing.

Authors:  X Q Qi; R L Sun; C J Tang; F Z Wang; Y M Ruan; R L Gao; Y L Li; S Q Tao; R S Cai
Journal:  Chin Med J (Engl)       Date:  1991-08       Impact factor: 2.628

10.  Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era.

Authors:  Frédéric Sacher; Piotr Sobieszczyk; Usha Tedrow; Andrew C Eisenhauer; Michael E Field; Andrew Selwyn; Jean-Marc Raymond; Bruce Koplan; Laurence M Epstein; William G Stevenson
Journal:  Heart Rhythm       Date:  2007-09-19       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.